Mk. b51 en es it fr

Mk. b51 Brand names, Mk. b51 Analogs

Mk. b51 Brand Names Mixture

  • No information avaliable

Mk. b51 Chemical_Formula


Mk. b51 RX_link

Mk. b51 fda sheet

Mk._b51 FDA

Mk. b51 msds (material safety sheet)

Mk._b51 MSDS

Mk. b51 Synthesis Reference

No information avaliable

Mk. b51 Molecular Weight

1270.28 g/mol

Mk. b51 Melting Point

No information avaliable

Mk. b51 H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Mk. b51 State


Mk. b51 LogP

No information avaliable

Mk. b51 Dosage Forms

Powder for solution (for injection)

Mk. b51 Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Mk. b51 Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Mk. b51 Absorption

No information avaliable

Mk. b51 side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Mk. b51 Patient Information

No information avaliable

Mk. b51 Organisms Affected

Aspergillis, Candida and other fungi